Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00121017
Status:
WITHDRAWN
Last Update Posted:
2006-07-27
First Post:
2005-07-14
Brief Title:
A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated HIV-1HCV Co-Infected Subjects
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
A Randomized Open-Label Study Assessing Safety Tolerability and Efficacy of an Induction-Maintenance Treatment Strategy Including LopinavirRitonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine Versus Efavirenz Plus Tenofovir Disoproxil Fumarate and Emtricitabine in Antiviral-naïve HIV-1HCV Co-Infected Subjects
Status:
WITHDRAWN
Status Verified Date:
2006-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether a simplified lopinavirritonavir-based therapy will continue to keep the viral load at very low levels after initial treatment with a combination of Kaletra lopinavirritonavir plus tenofovir and emtricitabine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None